Samsung Bioepis Co., Ltd. has secured marketing approval in Korea for XBRYK, its biosimilar to Amgen’s bone cancer drug XGEVA, used to ...

Three Motley Fool contributors believe they've found no-brainer healthcare stocks to buy in June. (Amgen): One of the best ...

Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...

Europe’s economy is affected by these developments as it has only now begun to recover from recent shocks, its public spending needs are rising, public debt is high, and medium-term growth prospects ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

Amgen is no exception to this dynamic. Although 2017's Tax Cuts and Jobs Act spurred the company to build a handful of new ...

A seminal decision concerning second medical use patents and questions over confidentiality were among the top talking points ...

Tesla’s sales in Europe have dropped by nearly 40 percent since the start of the year. The downward trend has acutally accelerated, with sales falling over 46 percent in April. The issue extends ...

Amgen AMGN and Bristol Myers Squibb BMY are among the largest global biotechnology companies with broad and diverse portfolios. Amgen boasts one of the largest portfolios in the biotech industry ...

Amgen recently faced a legal setback, with a U.S. District Court jury finding the company liable for antitrust violations and awarding Regeneron Pharmaceuticals $406.8 million in damages.

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more. From STAT’s Andrew Joseph: Lars Fruergaard ...